Calliditas Therapeutics AB

General Information


We are a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Our lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments.

Employees: 24
Founded: 2004
Contact Information
Address Kungsbron 1, C8, SE-111 22, Stockholm, Sweden
Phone Number +46 (0) 8 411 3005
Web Address
View Prospectus: Calliditas Therapeutics AB
Financial Information
Market Cap
Revenues $18.8 mil (last 12 months)
Net Income $-9.8 mil (last 12 months)
IPO Profile
Symbol CALTX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Jefferies/ Stifel
CO-Managers Carnegie
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change